Maze Therapeutics, Inc. Common Stock
$22.52
-$0.92 (-3.92%)
$22.01Day Range$23.57
Key Statistics
Market Cap
$1.30B
Shares Outstanding
55.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jan 31, 2025
Round Lot
100
Locale
US
Trading Data
Day Open
$23.27
Day High
$23.57
Day Low
$22.01
Volume
1.49M
VWAP
$22.54
Prev Close
$23.44
Transactions
--
Acc. Volume
--
About Maze Therapeutics, Inc. Common Stock
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836141 employees171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080(650) 850-5070IPO Jan 31, 2025US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001842295
- Composite FIGI
- BBG00NHJHS27
- Share Class FIGI
- BBG00NHJHS36
- Ticker Root
- MAZE
- SIC Code
- 2836
About Maze Therapeutics, Inc. Common Stock (MAZE) Stock
Maze Therapeutics, Inc. Common Stock (MAZE) closed the 2026-09-18 session at $22.52, down 3.92% versus the previous close (-0.92). The stock opened at $23.27 and traded between $22.01 and $23.57 during that session. Session trading volume was 1.5M shares. The volume-weighted average price (VWAP) is $22.54.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Maze Therapeutics, Inc. Common Stock has a market capitalization of $1.30 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. MAZE is listed on the XNAS exchange. The company employs approximately 141 people. Maze Therapeutics, Inc. Common Stock is headquartered in SOUTH SAN FRANCISCO, CA. The recorded listing date is 2025-01-31.
On this page you can find market MAZE stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.